top of page

Dysport Celebrates 10 Years

Over the past 10 years, Dysport has established its legacy through various milestones – the brand is approved for clinical use in 72 countries, backed by over 25 years of clinical investigation worldwide in both therapeutic and aesthetic use, and has an established long-term safety profile with a 36-month long-term study.

Dysport 10 Years

Dysport is fast-acting and long-lasting with natural-looking results to smooth frown lines between the eyebrows. In clinical studies, more than half of users saw improvement in their frown lines in as little as 2-3 days and the results lasting for up to five months.(1-4)

Dysport also has a high patient satisfaction rate, with 97% of users+ saying they would receive the treatment again and recently, Dysport received a 97% "Worth It" rating on RealSelf, making it among the top 10 highest satisfaction ratings for all nonsurgical treatments in 2019.(5)

"Dysport's legacy on the market over the past decade is proof of Galderma's ongoing commitment to invest in innovation that drives an impact with our customers and their patients. Dysport has outgrown the market for the past three years and we anticipate continued growth through investments in additional clinical studies evaluating duration and patient satisfaction," said Alisa Lask, Vice President and General Manager of Galderma's U.S. Aesthetic Business. "The aesthetics market has grown exponentially since the approval of Dysport, and Galderma will remain focused on continuing to drive this growth by providing innovative products and services that help our customers grow their practices."

In addition to strong safety and efficacy, recent post-approval clinical studies have demonstrated Dysport patients experience results positively affecting their psychological well-being as well. When asked 30 days after their Dysport treatment, 92% of patients reported feeling confident, 90% of patients reported looking natural and 92% of patients felt they looked attractive. Even four months post-treatment, patients reported looking at least four years younger than their actual age.(6)

"As a loyal Dysport customer since its FDA approval, I'm pleased to celebrate this important milestone 10 years later," said Dr. Joel Schlessinger, board-certified dermatologist in Omaha, NE. "Dysport is a remarkable aesthetic product that has proven incredibly successful in my practice and I am grateful to have been involved in its clinical development and approval over 10 years ago. Since its approval, I have come to rely on the safe, effective and natural-looking results my patients receive with Dysport, and I appreciate Galderma's ongoing support to drive patients into my practice with consumer promotions."

Over 400,000 new Dysport patients are entering the ASPIRE Galderma Rewards program each year – a sign that the aesthetic market is continuing to grow rapidly. To celebrate this, Galderma is offering double points for Dysport aesthetic treatments registered in the consumer loyalty program through July 31, 2019, which patients can redeem for discounts on their next treatment. To earn exclusive rewards, bonuses and discounts on Galderma's aesthetic treatments, join the ASPIRE Rewards program. To learn more about ASPIRE, visit

The milestone of Dysport's 10-year FDA approval underscores Galderma's commitment to invest in innovations that impact patients' lives and their customers' success.

+ Users= clinical study subjects 1 Data on file. MA-Y-97-52120-719 (GL-1) Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2007. 2 Data on file. MA-Y-97-52120-718 (GL-3) Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2007. 3 Data on file. MA-Y-97-52120-085 (GL-2) Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2007. 4 Data on file. MA-35497. Post Hoc Analysis. Fort Worth, TX: Galderma Laboratories, L.P., 2017. 5 RealSelf. RealSelf Ranks the "Most Worth It" Surgical and Nonsurgical Aesthetic Procedures Based on Consumers' Worth It Ratings. 2019. 6 Data on file. GLI.04.SRE.US10348 Clinical Study Report. Fort Worth, TX: Galderma Laboratories, L.P., 2017.

bottom of page